Requirements

All of it, under the two minimums and the anonymity the answers set. A field signal is shown when at least 8 distinct people stand behind it (OQ-14) and, where it comes from OncoSkepsis, at least 3 distinct institutions with the 5 percent dominance check (OQ-40, NP-12). Counts are rounded to the nearest 5. Nobody is named: a pharma user sees an anonymous card, and an identity is revealed only when the expert or clinician accepts a contact request, which is stored as a consent record naming the company and the wording shown (OQ-05, OQ-42).

Still held. Nothing. Below either minimum there is nothing to show, and the view says so, naming the minimum rather than rendering an empty result that reads as a quiet field.

Released by OQ-05, OQ-14, OQ-40, OQ-42, NP-12.

All of it. The trigger is the OQ-06 topic score crossing the NP-15 cut-off, the top 1.4 percent within a disease area, rather than a question count nobody stated. Delivery is the weekly digest and the CRM task of OQ-22. What the alert may say is bounded by the same minimums as any other view, and it names no expert who has not accepted a contact request (OQ-05, OQ-14, OQ-42).

Still held. Nothing. The cut-off is configuration, because the validation study of OQ-27 replaces it with a measured one, and an alert threshold that needed a release to change is a threshold nobody will tune.

Released by OQ-05, OQ-06, OQ-14, OQ-22, OQ-42, NP-15.

The sustained-enquiry indicator for a clinician, reaching a pharma user as an anonymous card and never a name. An identity is revealed only when that clinician accepts a specific contact request, and the acceptance is stored as a consent record holding the time, the wording shown and the company named (OQ-05, OQ-42).

Still held. Nothing. Shown only above both minimums: 8 distinct contributing people (OQ-14) and 3 distinct institutions with the 5 percent dominance check (OQ-40, NP-12), with counts rounded to the nearest 5 and the differencing check refusing an export or API answer whose comparison could reveal a hidden count (NP-10).

Released by OQ-05, OQ-42.

All of it. The consent screen can now say what it has to, because the answers fix what is recorded: coded labels plus a machine-written topic summary, never a clinician's typed words (OQ-38); no free-text question box exists at all (OQ-39); the ISO week and no timestamp (OQ-43); and a name reaching a pharma user only through the clinician's own acceptance of a contact request (OQ-05, OQ-42).

Still held. Nothing. A consent screen is only as honest as the list behind it, which is why this requirement could not be built while any of those four answers was missing.

Released by OQ-05, OQ-38, OQ-39, OQ-42, OQ-43.

All of it, confirmed by OQ-42 and OQ-46: a clinician is anonymous until they accept a specific contact request, the acceptance is stored with its time, wording and the company named, and tumour-board membership appears only inside the profile that acceptance opens (NP-02).

Still held. Nothing.

Released by OQ-05, OQ-42, OQ-46, NP-02.